FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:907-912 October 5, 1995 Number 14 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Investigations of outbreaks of multidrug-resistant tuberculosis have found low rates of treatment response and very high mortality, and they have mainly involved patients with advanced human immunodeficiency virus (HIV) infection. For patients without HIV infection, one study reported an overall rate of response to treatment of 56 percent, and the mortality from tuberculosis was 22 percent. We investigated treatment response and mortality rates in 26 HIV-negative patients in New York with multidrug-resistant tuberculosis.

Methods We obtained detailed data from seven teaching hospitals in New York City on patients with multidrug-resistant tuberculosis — defined as tuberculosis resistant at least to isoniazid and rifampin — who were HIV-negative on serologic testing. Lengths of times from diagnosis to the initiation of appropriate therapy and from the initiation of appropriate therapy to conversion to negative cultures were assessed. Therapeutic responses were evaluated by both microbiologic and clinical criteria.

Results Between March 1991 and September 1994, 26 HIV-negative patients were identified and treated. Of the 25 patients for whom adequate data were available for analysis, 24 (96 percent) had clinical responses; all 17 patients for whom data on microbiologic response were available had such a response. The median times from diagnosis to the initiation of appropriate therapy and from the initiation of therapy to culture conversion were 44 days (range, 0 to 181) and 69 days (range, 2 to 705), respectively. Side effects requiring the discontinuation of medication occurred in 4 of 23 patients (17 percent) who were treated with second-line antituberculosis medications. The median follow-up for the 23 patients who responded and who received appropriate therapy was 91 weeks (range, 41 to 225).

Conclusions In this report from New York City, HIV-negative patients with multidrug-resistant tuberculosis, contrary to previous reports, responded well to appropriate chemotherapy, both clinically and microbiologically.

Source Information

From the Bronx–Lebanon Hospital Center, Bronx, N.Y. (E.E.T., S.B., G.T.); St. Clare's Hospital and Health Center, New York (K.S.); New York Hospital–Cornell Medical Center, New York (K.S., S.M.); Harlem Hospital Center, New York (F.M., W.E.-S.); Montefiore Medical Center and North Central Bronx Hospital, Bronx, N.Y. (P.A.); St. Vincent's Medical Center, New York (A.G.); and Beth Israel Medical Center, New York (N.S.).

Address reprint requests to Dr. Telzak at the Division of Infectious Diseases, Bronx–Lebanon Hospital Center, Albert Einstein College of Medicine, 1650 Grand Concourse, Bronx, NY 10457.

Full Text of this Article

Related Letters:

Multidrug-Resistant Tuberculosis
Iseman M. D., Goble M., Corrêa da Silva L. C., Corrêa da Silva L. M., Di Perri G., Vento S., Concia E., Cazzadori A., Telzak E. E., Sepkowitz K., Turett G.
Extract | Full Text  
N Engl J Med 1996; 334:267-269, Jan 25, 1996. Correspondence

This article has been cited by other articles:

• Bravo, L. T. C., Tuohy, M. J., Ang, C., Destura, R. V., Mendoza, M., Procop, G. W., Gordon, S. M., Hall, G. S., Shrestha, N. K. (2009). Pyrosequencing for Rapid Detection of Mycobacterium tuberculosis Resistance to Rifampin, Isoniazid, and Fluoroquinolones. J. Clin. Microbiol. 47: 3985-3990 [Abstract] [Full Text]  
• Drobac, P. C., Mukherjee, J. S., Joseph, J. K., Mitnick, C., Furin, J. J., del Castillo, H., Shin, S. S., Becerra, M. C. (2006). Community-based therapy for children with multidrug-resistant tuberculosis.. Pediatrics 117: 2022-2029 [Abstract] [Full Text]  
• Chambers, H. F., Turner, J., Schecter, G. F., Kawamura, M., Hopewell, P. C. (2005). Imipenem for Treatment of Tuberculosis in Mice and Humans. Antimicrob. Agents Chemother. 49: 2816-2821 [Abstract] [Full Text]  
• Ormerod, L. P. (2005). Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 73-74: 17-24 [Abstract] [Full Text]  
• Naidoo, R., Reddi, A. (2005). Lung Resection for Multidrug-Resistant Tuberculosis. Asian Cardiovasc. Thorac. Ann. 13: 172-174 [Abstract] [Full Text]  
• Caminero, J. A. (2005). Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 25: 928-936 [Abstract] [Full Text]  
• Di Perri, G., Bonora, S. (2004). Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?. J Antimicrob Chemother 54: 593-602 [Abstract] [Full Text]  
• Sterling, T. R, Lehmann, H. P, Frieden, T. R (2003). Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 326: 574-574 [Abstract] [Full Text]  
• Farmer, P., Gastineau, N. (2002). Rethinking Health and Human Rights: Time for a Paradigm Shift. J Law Med Ethics 30: 655-666  
• Drobniewski, F, Eltringham, I, Graham, C, Magee, J G, Smith, E G, Watt, B (2002). A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax 57: 810-816 [Abstract] [Full Text]  
• Maccari, R., Ottana, R., Monforte, F., Vigorita, M. G. (2002). In Vitro Antimycobacterial Activities of 2'-Monosubstituted Isonicotinohydrazides and Their Cyanoborane Adducts. Antimicrob. Agents Chemother. 46: 294-299 [Abstract] [Full Text]  
• Brewer, T. F., Heymann, S. J., Krumplitsch, S. M., Wilson, M. E., Colditz, G. A., Fineberg, H. V. (2001). Strategies to Decrease Tuberculosis in US Homeless Populations: A Computer Simulation Model. JAMA 286: 834-842 [Abstract] [Full Text]  
• Narita, M., Alonso, P., Lauzardo, M., Hollender, E. S., Pitchenik, A. E., Ashkin, D. (2001). Treatment Experience of Multidrug-Resistant Tuberculosis in Florida, 1994-1997. Chest 120: 343-348 [Abstract] [Full Text]  
• Tahaoglu, K., Torun, T., Sevim, T., Atac, G., Kir, A., Karasulu, L., Ozmen, I., Kapakli, N. (2001). The Treatment of Multidrug-Resistant Tuberculosis in Turkey. NEJM 345: 170-174 [Abstract] [Full Text]  
• Farmer, P. E. (2000). The Consumption of the Poor: Tuberculosis in the 21st Century. Ethnography 1: 183-216 [Abstract]  
• Long, R. (2000). Drug-resistant tuberculosis. CMAJ 163: 425-428 [Abstract] [Full Text]  
• Espinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baez, J., Kochi, A., Dye, C., Raviglione, M. C. (2000). Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis: Treatment Outcomes in 6 Countries. JAMA 283: 2537-2545 [Abstract] [Full Text]  
• Horsburgh, C. R. Jr (2000). The Global Problem of Multidrug-Resistant Tuberculosis: The Genie Is out of the Bottle. JAMA 283: 2575-2576 [Full Text]  
• Yew, W. W., Chan, C. K., Chau, C. H., Tam, C. M., Leung, C. C., Wong, P. C., Lee, J. (2000). Outcomes of Patients With Multidrug-Resistant Pulmonary Tuberculosis Treated With Ofloxacin/Levofloxacin-Containing Regimens. Chest 117: 744-751 [Abstract] [Full Text]  
• DROBNIEWSKI, F.A., WATTERSON, S.A., WILSON, S.M., HARRIS, G.S. (2000). A clinical, microbiological and economic analysis of a national service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis. J Med Microbiol 49: 271-278 [Abstract] [Full Text]  
• FLAMENT-SAILLOUR, M., ROBERT, J., JARLIER, V., GROSSET, J. (1999). Outcome of Multi-drug-resistant Tuberculosis in France . A Nationwide Case-Control Study. Am. J. Respir. Crit. Care Med. 160: 587-593 [Abstract] [Full Text]  
• Heymann, S. J., Brewer, T. F., Wilson, M. E., Fineberg, H. V. (1999). The Need for Global Action Against Multidrug-Resistant Tuberculosis. JAMA 281: 2138-2140 [Full Text]  
• Chan-Tack, K. M., Diaz, J. F., Geerligs, W. A., van Altena, R., van der Werf, T. S., Pablos-Mendez, A., Raviglione, M. C., Nunn, P. (1998). Antituberculosis-Drug Resistance. NEJM 339: 1079-1080 [Full Text]  
• Telenti, A (1998). Genetics and pulmonary medicine bullet  5: Genetics of drug resistant tuberculosis. Thorax 53: 793-797 [Full Text]  
• Pablos-Mendez, A., Sterling, T. R., Frieden, T. R. (1996). The Relationship Between Delayed or Incomplete Treatment and All-Cause Mortality in Patients With Tuberculosis. JAMA 276: 1223-1228 [Abstract]  
• Frieden, T. R., Sherman, L. F., Maw, K. L., Fujiwara, P. I., Crawford, J. T., Nivin, B., Sharp, V., Hewlett, D. Jr, Brudney, K., Alland, D., Kreiswirth, B. N. (1996). A Multi-institutional Outbreak of Highly Drug-Resistant Tuberculosis: Epidemiology and Clinical Outcomes. JAMA 276: 1229-1235 [Abstract]  
• Bishai, W. R., Graham, N. M.H., Harrington, S., Page, C., Moore-Rice, K., Hooper, N., Chaisson, R. E. (1996). Rifampin-Resistant Tuberculosis in a Patient Receiving Rifabutin Prophylaxis. NEJM 334: 1573-1576 [Full Text]  
• Bloch, A. B., Simone, P. M., McCray, E., Castro, K. G. (1996). Preventing Multidrug-Resistant Tuberculosis. JAMA 275: 487-489 [Abstract]  
• Iseman, M. D., Goble, M., Correa da Silva, L. C., Correa da Silva, L. M., Di Perri, G., Vento, S., Concia, E., Cazzadori, A., Telzak, E. E., Sepkowitz, K., Turett, G. (1996). Multidrug-Resistant Tuberculosis. NEJM 334: 267-269 [Full Text]